NephMadness 2015: The Heart and Kidney Connection Region
Submit your picks! | For more on NephMadness 2015 | #NephMadness or #HeartRegion on Twitter This region is like the Showtime Lakers of the 80s. Cardiology always packs the [...]
TolvaptaninHF
Inappropriate increases in vasopressin contribute to water retention in heart failure. Therefore, vasopressin receptor blockade with tolvaptan represents a potential therapeutic intervention in heart failure. The EVEREST trial reported in the NEJM evaluated the use of tolvaptan versus placebo in patients with decompensated acute heart failure. However, in the EVEREST trial treatment with tolvaptan versus placebo showed no difference in long term mortality or heart failure morbidity in patients with decompensated acute heart failure. Tolvaptan’s utility in chronic heart failure is still under investigation.